Iovance Biotherapeutics price target raised to $25 from $22 at Wells Fargo

Wells Fargo analyst Yanan Zhu raised the firm’s price target on Iovance Biotherapeutics to $25 from $22 and keeps an Overweight rating on the shares. The firm thinks the Amtagvi launch is off to a strong start, with 20 patients enrolled in just 12 days, the analyst tells investors in a research note, adding that it sees further ramp-up in patient-starts from the already respectable base.